 In a report released today,Mayank Mamtanifrom B.Riley FBR reiterated aBuyrating on Allena Pharmaceuticals ALNAResearch Report, with a price target of4.00. The companys shares closed last Monday at 0.59, close to its 52-week low of 0. 